Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial

医学 奥司他韦 安慰剂 内科学 人口 随机对照试验 儿科 临床终点 疾病 病理 替代医学 环境卫生 2019年冠状病毒病(COVID-19) 传染病(医学专业)
作者
Michael G. Ison,Simon Portsmouth,Yuki Yoshida,Takao Shishido,Melissa Mitchener,Kenji J. Tsuchiya,Takeki Uehara,Frederick G. Hayden
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:20 (10): 1204-1214 被引量:255
标识
DOI:10.1016/s1473-3099(20)30004-9
摘要

Baloxavir marboxil (hereafter baloxavir), a selective inhibitor of influenza cap-dependent endonuclease, was approved in 2018 in the USA and Japan for the treatment of uncomplicated influenza in otherwise healthy individuals aged 12 years and older. We aimed to study the efficacy of baloxavir in outpatients at high risk of developing influenza-associated complications.We did a double-blind, placebo-controlled and oseltamivir-controlled trial in outpatients aged 12 years and older in 551 sites in 17 countries and territories. Eligible patients had clinically diagnosed influenza-like illness, at least one risk factor for influenza-associated complications (eg, age older than 65 years), and a symptom duration of less than 48 h. Patients were stratified by baseline symptom score (≤14 vs ≥15), pre-existing and worsened symptoms at onset of illness compared with pre-influenza (yes or no), region (Asia, North America and Europe, or southern hemisphere), and weight (<80 kg vs ≥80 kg), and randomly assigned (1:1:1) via an interactive web-response system to either a single weight-based dose of baloxavir (40 mg for patients weighing <80 kg and 80 mg for patients weighing ≥80 kg; baloxavir group), oseltamivir 75 mg twice daily for 5 days (oseltamivir group), or matching placebo (placebo group). All patients, investigators, study personnel, and data analysts were masked to treatment assignment until database lock. The primary endpoint was time to improvement of influenza symptoms (TTIIS) in the modified intention-to-treat population, which included all patients who received at least one dose of study drug and had RT-PCR-confirmed influenza virus infection. Safety was assessed in all patients who receved at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT02949011.2184 patients were enrolled from Jan 11, 2017, to March 30, 2018, and randomly assigned to receive baloxavir (n=730), placebo (n=729), or oseltamivir (n=725). The modified intention-to-treat population included 1163 patients: 388 in the baloxavir group, 386 in the placebo group, and 389 in the oseltamivir group. 557 (48%) of 1163 patients had influenza A H3N2, 484 (42%) had influenza B, 80 (7%) had influenza A H1N1, 14 patients had a mixed infection, and 28 had infections with non-typable viruses. The median TTIIS was shorter in the baloxavir group (73·2 h [95% CI 67·2 to 85·1]) than in the placebo group (102·3 h [92·7 to 113·1]; difference 29·1 h [95% CI 14·6 to 42·8]; p<0·0001). The median TTIIS in the oseltamivir group was 81·0 h (95% CI 69·4 to 91·5), with a difference from the baloxavir group of 7·7 h (-7·9 to 22·7). Adverse events were reported in 183 (25%) of 730 patients in the baloxavir group, 216 (30%) of 727 in the placebo group, and 202 (28%) of 721 in the oseltamivir group. Serious adverse events were noted in five patients in the baloxavir group, nine patients in the placebo group, and eight patients in the oseltamivir group; one case each of hypertension and nausea in the placebo group and two cases of transaminase elevation in the oseltamivir group were considered to be treatment related. Polymerase acidic protein variants with Ile38Thr, Ile38Met, or Ile38Asn substitutions conferring reduced baloxavir susceptibility emerged in 15 (5%) of 290 baloxavir recipients assessed for amino acid substitutions in the virus.Single-dose baloxavir has superior efficacy to placebo and similar efficacy to oseltamivir for ameliorating influenza symptoms in high-risk outpatients. The safety of baloxavir was comparable to placebo. This study supports early therapy for patients at high risk of complications of influenza to speed clinical recovery and reduce complications.Shionogi.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
侯锐淇完成签到 ,获得积分10
刚刚
ggjun完成签到,获得积分10
7秒前
10秒前
干净的雅青完成签到,获得积分10
16秒前
momo完成签到,获得积分10
16秒前
Lucas的应助被猪猪hero采纳,获得10
22秒前
落落完成签到 ,获得积分10
25秒前
FAHUO完成签到,获得积分10
29秒前
孤独的芹菜完成签到,获得积分10
33秒前
王耑完成签到 ,获得积分10
36秒前
清影完成签到,获得积分10
37秒前
38秒前
Wang发布了新的文献求助10
44秒前
鹏liu完成签到,获得积分10
47秒前
活力以冬完成签到,获得积分10
49秒前
开朗含海完成签到,获得积分10
49秒前
Heby完成签到 ,获得积分10
52秒前
amiee发布了新的文献求助10
55秒前
酷炫蛋挞完成签到 ,获得积分10
57秒前
tough_cookie完成签到 ,获得积分10
57秒前
求知小生完成签到 ,获得积分10
58秒前
1分钟前
前方的菜鸟完成签到 ,获得积分10
1分钟前
花花子完成签到 ,获得积分10
1分钟前
syvshc的应助被科研通管家采纳,获得10
1分钟前
cssc完成签到,获得积分10
1分钟前
arniu2008的应助被科研通管家采纳,获得20
1分钟前
Owen的应助被科研通管家采纳,获得10
1分钟前
懒猫完成签到,获得积分10
1分钟前
鹏liu发布了新的文献求助10
1分钟前
凌泉完成签到 ,获得积分10
1分钟前
英姑的应助被shally采纳,获得10
1分钟前
1分钟前
淡然雅彤完成签到,获得积分10
1分钟前
画龙点睛完成签到 ,获得积分10
1分钟前
shally发布了新的文献求助10
1分钟前
虚幻烤鸡完成签到,获得积分10
1分钟前
梦瑶完成签到 ,获得积分10
1分钟前
ziqizhou完成签到 ,获得积分10
1分钟前
Firewoods完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185502
求助须知:如何正确求助?哪些是违规求助? 9574242
关于积分的说明 21834586
捐赠科研通 7783123
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481357